Wang Junqi, Zhang Ruiguo
Department of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, China.
Br J Radiol. 2017 Mar;90(1071):20160836. doi: 10.1259/bjr.20160836. Epub 2017 Jan 20.
Amiodarone-induced thyrotoxicosis (AIT) is caused by amiodarone as a side effect of cardiovascular disease treatment. Based on the differences in their pathological and physiological mechanisms, many methods have been developed so far to differentiate AIT subtypes such as colour flow Doppler sonography (CFDS) and 24-h radioiodine uptake (RAIU). However, these methods suffer from inadequate accuracy in distinguishing different types of AITs and sometimes lead to misdiagnosis and delayed treatments. Therefore, there is an unmet demand for an efficient method for accurate classification of AIT.
Technetium-99 methoxyisobutylisonitrile (Tc-MIBI) thyroid imaging was performed on 15 patients for AIT classification, and the results were compared with other conventional methods such as CFDS, RAIU and TcO imaging.
High uptake and retention of MIBI in thyroid tissue is characteristic in Type I AIT, while in sharp contrast, low uptake of MIBI in the thyroid tissue was observed in Type II AIT. Mixed-type AIT shows uptake value between Types I and II. MIBI imaging outperforms other methods with a lower misdiagnosis rate.
Among the methods evaluated, MIBI imaging enables an accurate identification of Type I, II and mixed-type AITs by showing distinct images for different types of AITs. The results obtained from our selected subjects revealed that MIBI imaging is a reliable method for diagnosis and classification of AITs and MIBI imaging has potential in the treatment of thyroid diseases. Advances in knowledge: Tc-MIBI imaging is a useful method for the diagnosis of AIT. It can distinguish different types of AITs especially for mixed-type AIT, which is usually difficult to treat. Tc-MIBI has potential advantages over conventional methods in the efficient treatment of AIT.
胺碘酮诱发的甲状腺毒症(AIT)是胺碘酮作为心血管疾病治疗副作用所导致的。基于其病理生理机制的差异,目前已开发出多种方法来区分AIT亚型,如彩色多普勒超声(CFDS)和24小时放射性碘摄取(RAIU)。然而,这些方法在区分不同类型的AIT时准确性不足,有时会导致误诊和治疗延误。因此,对于一种高效准确分类AIT的方法仍有未满足的需求。
对15例AIT患者进行锝-99甲氧基异丁基异腈(Tc-MIBI)甲状腺显像以进行AIT分类,并将结果与CFDS、RAIU和TcO显像等其他传统方法进行比较。
I型AIT的特征是甲状腺组织中MIBI摄取和滞留高,而与之形成鲜明对比的是,II型AIT甲状腺组织中MIBI摄取低。混合型AIT的摄取值介于I型和II型之间。MIBI显像优于其他方法,误诊率更低。
在所评估的方法中,MIBI显像通过显示不同类型AIT的独特图像,能够准确识别I型、II型和混合型AIT。从我们所选受试者获得的结果表明,MIBI显像是诊断和分类AIT的可靠方法,且MIBI显像在甲状腺疾病治疗中具有潜力。知识进展:Tc-MIBI显像是诊断AIT的一种有用方法。它可以区分不同类型的AIT,尤其是对于通常难以治疗的混合型AIT。在AIT的有效治疗方面,Tc-MIBI比传统方法具有潜在优势。